scispace - formally typeset
H

Hanxiang Nie

Researcher at Wuhan University

Publications -  33
Citations -  853

Hanxiang Nie is an academic researcher from Wuhan University. The author has contributed to research in topics: Medicine & Asthma. The author has an hindex of 9, co-authored 26 publications receiving 372 citations.

Papers
More filters
Journal ArticleDOI

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.

TL;DR: In this paper, the authors describe the temporal trends in respiratory outcomes over 12 months in patients hospitalised for severe COVID-19 and investigate the associated risk factors, including a history of hypertension, diabetes, cardiovascular disease, cancer, and chronic lung disease, including asthma or chronic obstructive pulmonary disease.
Journal ArticleDOI

Risk factors associated with disease severity and length of hospital stay in COVID-19 patients.

TL;DR: Department of Pulmonary and Critical Care Medicine, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhian, Hubei, China; Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Journal ArticleDOI

Abnormal immunity of non-survivors with COVID-19: predictors for mortality.

TL;DR: The clinical characteristics and abnormal immunity of the confirmed COVID-19 non-survivors, including significantly older than survivors, and the immunity-related risk factors associated with in-hospital death were tested.
Journal ArticleDOI

Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis.

TL;DR: The older patients with COVID-19 who had underlying chronic disorders are more likely to develop leukocytosis, with a high admission to an ICU and a high mortality rate.
Journal ArticleDOI

Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma

TL;DR: The data reveal that type II NKT cells activated by glycolipids, such as sulfatide, may serve as a novel approach to treat allergic diseases and other disorders characterized by inappropriate type I NKT cell activation.